Preclinical and clinical safety data includes [5] : No evidence of mutagenic activity, chromosomal aberrations, or micronucleus formation in genotoxicity studies 6-month chronic oral administration studies in rats showed no toxicological concerns 9-month studies in cynomolgus monkeys revealed general safety Six human clinical trials spanning 0.25 mg to 30 mg doses for up to 6 months No serious adverse events or withdrawals related to AOD9604 intake No anti-AOD9604 antibodies detected, indicating low immunogenic potential No changes in vital signs, physical examinations, electrocardiograms, or safety-related laboratory parameters Research Applications A Quick Review AOD9604 is a peptide compound that has shown potential in research related to lipid metabolism, energy balance, and tissue regeneration
This represents a modulatory rather than direct agonist/antagonist profile that distinguishes it from conventional dopaminergic drugs
This usually occurs in individuals with underlying digestive conditions, those who have trouble absorbing all nutrients through digestion, or those with pernicious anemia, which specifically prevents B12 absorption
Porter et al., 2003
This and the conserved disulfide bond between two Cys residues may also make AOD9604 resistant to proteolysis and low pH